Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $15.8 million, a decline of $2.4 million or 13% year-over-year [24][6] - Lease revenue decreased by $3.5 million or 58% year-over-year in Q4, offsetting mid-teens growth in cash system sales [7][6] - Net loss attributable to stockholders for Q4 2024 was $8 million or $11.23 per share, compared to a net loss of $11.1 million or $20.14 per share for Q4 2023 [32] Business Line Data and Key Metrics Changes - Cash system sales in the U.S. increased by 27% year-over-year, representing 87% of total U.S. system sales in Q4 compared to 58% last year [8] - The percentage of total systems revenue from internal lease programs decreased from approximately 41% in the prior year to 20% in Q4 2024 [25] - Sales through distributors more than doubled year-over-year in Q4, particularly in the APAC and EMEA regions [12] Market Data and Key Metrics Changes - Revenue results in fiscal year 2024 reflected a decline of 15% year-over-year, which was better than many competitors [13] - The decline in total revenue was driven by a 13% decrease in both U.S. and international revenue [24][25] - Customer financing pressures and economic uncertainty continue to impact system adoption [10] Company Strategy and Development Direction - The company is focused on transitioning to cash system sales, aiming for 70% to 75% of total systems revenue to come from cash sales [26] - A strategic initiative to restructure debt obligations resulted in a 47% reduction in total debt from $74.9 million to approximately $39.7 million [17] - The company plans to launch a new body system in the second half of 2025, which is expected to drive growth [55] Management's Comments on Operating Environment and Future Outlook - Management acknowledges that macroeconomic headwinds will continue to impact quarterly performance but remains optimistic about returning to growth [14][36] - The company is not providing full-year 2025 financial guidance but expects total revenue for Q1 2025 to be at least $14 million [36] - Management believes that the impact of strategic transitions is behind them, looking forward to a more normalized business profile [13][42] Other Important Information - A 1 for 11 reverse stock split was announced, with the company's common stock trading on an adjusted basis starting March 4, 2025 [21] - The company has made significant progress in reducing cash used in operations by 14% year-over-year [15] Q&A Session Summary Question: Can you characterize what a normal business profile is going forward? - Management indicated that while predicting the macroeconomic environment is challenging, they expect performance to improve compared to 2024 [42] Question: How is the Venus Hair business performing? - Management expressed satisfaction with the performance of the Venus Hair business, particularly the Venus ARTAS Robot, and noted ongoing R&D innovations [46][47] Question: What is the strategy for top-line growth in 2025? - Management highlighted the need to establish a normal rhythm of orders with new distribution partners and anticipates growth in international business [53][54] Question: Are there further cost-cutting measures available? - Management stated that the infrastructure is efficient, and the focus is on increasing sales rather than further cost reductions [57] Question: How do tariffs affect the business? - Management noted that products are manufactured in both the U.S. and Israel, and currently, they do not expect a substantial near-term impact from tariffs [60]

Westport Fuel Systems Inc (WPRT) Q4 2024 Earnings Conference Call March 31, 2025 01:30 PM ET Company Participants Ashley - Vice President of Investor RelationsConference Call Operator - OperatorConference Call Operator - OperatorConference Call Operator - OperatorDan Selis - Chief Executive Officer and DirectorBill Larkin - Chief Financial Officer Conference Call Participants Chris Dendrinos - Analyst, RBC Capital MarketsEric Stein - Analyst, Craig Hallam Capital GroupRob Brown - Analyst, Lake Street Capita ...

Chicago Atlantic BDC (LIEN) Q4 2024 Earnings Call March 31, 2025 01:07 PM ET Company Participants Tripp Sullivan - Investor Relations, SCR PartnersPeter Sack - CEOMartin Rodgers - CFODino Colonna - PresidentPablo Zuanic - Managing Partner Operator Good morning, and welcome to the Chicago Atlantic BDC Fourth Quarter twenty twenty four Conference Call. All participants will be in listen only mode. Please note this event is being recorded. I would now like to turn the conference over to Tripp Sullivan of Inves ...

IM Cannabis Corp. (NASDAQ:IMCC) Q4 2024 Earnings Conference Call March 31, 2025 9:00 AM ET Company Participants Anna Taranko - Director of Investor and Public Relations Oren Shuster - Chairman and Chief Executive Officer Uri Birenberg - Chief Financial Officer Conference Call Participants Aaron Grey - Alliance Global Partners Operator Good morning and welcome to IM Cannabis' Fourth Quarter and Full Year 2024 Earnings Conference Call. Today's conference call is being recorded. At this time, I would like to t ...

KULR Technology Group (KULR) Q4 2024 Earnings Call March 31, 2025 12:33 PM ET Company Participants Stuart Smith - OwnerMichael Mo - Chairman, CEO & PresidentShawn Canter - Chief Financial Officer Stuart Smith Good afternoon and thank you for joining us for the Cooler Technology Group fourth quarter and full year twenty twenty four earnings call. Joining me on the call today will be Michael Moe, the Chief Executive Officer of the company, as well as Sean Kanter, the Chief Financial Officer of the company. I ...

Ironwood Pharmaceuticals (IRWD) Q4 2024 Earnings Call March 31, 2025 12:02 PM ET Company Participants Greg Martini - CFOThomas McCourt - CEOMichael Shetzline - SVP, Chief Medical Officer and Head of Research & DevelopmentJason Butler - Managing Director & Biotechnology Equity ResearchKatherine Wang - Equity AssociateMatthew Cowper - Vice President - Equity Research Conference Call Participants Chase Knickerbocker - Senior Equity Research Analyst - HealthcareDavid Amsellem - Sr. Research Analyst Operator My ...

Venus Concept Inc. (NASDAQ:VERO) Q4 2024 Earnings Conference Call March 31, 2025 8:00 AM ET Company Participants Rajiv De Silva - CEO Domenic Della Penna - EVP and CFO Conference Call Participants Marie Thibault - BTIG Jeremy Pearlman - Maxim Group Operator Good day, ladies and gentlemen, and welcome to the Fourth Quarter and Fiscal Year 2024 Earnings Conference Call for Venus Concept Inc. At this time, all participants have been placed in a listen-only mode. Please note that this conference call is being r ...

Financial Data and Key Metrics Changes - In the fourth quarter, net sales were $160 million, a decrease of $38 million or 19% compared to the same period in 2023, aligning with planned lower volumes [25] - New unit sales declined by 7% or approximately 92 units, while the average selling price for new units grew by 3% [24] - Pre-owned retail unit sales, including consigned vehicles, were down 23% or 268 units during the quarter [25] - SG&A expenses increased to $53 million for the quarter from $46 million in the prior year, primarily due to higher transaction and legal expenses related to restructuring [26] - Adjusted EBITDA loss was $24 million compared to a loss of $11 million in the prior year period [27] Business Line Data and Key Metrics Changes - On a same-store basis, there was a decline in both new and used unit volume, partially offset by improved gross profit per unit sold [15] - Total gross margin was 19% in the fourth quarter compared to 21% in the third quarter of 2024; excluding inventory and LIFO adjustments, gross margin was 23% [16] - Finance and Insurance (F&I) revenue was over $6,000 per unit, up 3% relative to the third quarter [16] Market Data and Key Metrics Changes - The company’s new inventory is comprised of 75% model year 2025 units and 25% prior model year units, with over 77% of new inventory being towable products [17] - Motorized inventory decreased by 44% from the prior year's period due to aggressive inventory management [18] Company Strategy and Development Direction - The company is focused on rightsizing its dealership portfolio to de-lever its balance sheet and improve earnings power [9] - A letter of intent has been signed to divest three locations, which will add cash to the balance sheet and reduce indebtedness [11] - The company aims to improve operational performance across all functional areas of its dealerships, including inventory, sales, service, F&I, and marketing [21] Management's Comments on Operating Environment and Future Outlook - Management acknowledged that 2024 was a year of significant transformation and that the company is executing a turnaround plan [7] - There is optimism that the company is near the bottom of a prolonged market down cycle, with expectations for future retail demand for RVs to return to historical levels [21] - Management expressed confidence in the company’s ability to drive improved results for stakeholders [27] Other Important Information - The company completed a comprehensive recapitalization, including a $30 million common equity investment and the exchange of convertible preferred stock for common stock [7] - The company reduced floor plan debt by $11 million and term loan debt by $6 million during the quarter [27] Q&A Session Summary - No questions were fielded following the prepared remarks, and the call concluded without a Q&A session [5][30]

Financial Data and Key Metrics Changes - Curis reported a net loss of $9.6 million or $1.25 per share for Q4 2024, compared to a net loss of $117 million or $2.03 per share for the same period in 2023 [19] - For the full year 2024, the net loss was $43.4 million or $6.88 per share, compared to a net loss of $47.4 million or $8.96 per share in 2023 [19] - Research and development expenses were $9 million for Q4 2024, down from $10 million in Q4 2023, primarily due to lower clinical and research costs [19][20] - General and administrative expenses decreased to $3.4 million in Q4 2024 from $4.9 million in Q4 2023, attributed to lower legal and consulting costs [20][21] Business Line Data and Key Metrics Changes - In the NHL segment, the TakeAim Lymphoma study is evaluating emavusertib in combination with ibrutinib, with positive feedback from EMA and FDA regarding potential accelerated approval pathways [6][12] - The study has 30 clinical sites open for enrollment, aiming to complete enrollment in the next 12 to 18 months [8][12] - In the AML segment, emavusertib showed a 38% composite CR rate in a study involving patients with FLT3 mutations, indicating strong efficacy compared to existing treatments [14][15] Market Data and Key Metrics Changes - The company has received Orphan Drug Designation for emavusertib in primary CNS lymphoma in both the U.S. and Europe, enhancing its market position [12] - The discussions with regulatory agencies indicate a favorable environment for potential approvals, as there are currently no approved treatments for primary CNS lymphoma [43] Company Strategy and Development Direction - The company is focused on accelerating the development timeline for emavusertib, with plans to enroll additional patients to support filings for accelerated approval [8][12] - There is an ongoing strategy to explore partnerships with major players in the NHL and AML spaces, indicating a proactive approach to enhance its market presence [28] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the clinical data and the clarity received from regulatory agencies, which supports the company's development plans [12][42] - The company anticipates maintaining a cash runway into Q4 2025, with a quarterly burn rate of approximately $10 million [26][22] Other Important Information - The company completed a registered direct offering and private placement with net proceeds of approximately $10.8 million, extending its financial runway [21] - The company is currently conducting a Phase 1 study of emavusertib in combination with venetoclax and azacitidine for frontline AML, with ongoing enrollment [16][52] Q&A Session Summary Question: Can you talk about cash runway and expenses going forward? - Management confirmed a quarterly burn rate of about $10 million, extending the cash runway to Q4 2025 due to recent offerings [26] Question: Any potential inbound interest from partners? - Management indicated ongoing discussions with potential partners, given the promising data in NHL and AML [28] Question: How many patients have been dosed with emavusertib? - A total of 13 patients have been dosed at 100 mg BID in the study [35] Question: What does the EMA expect in terms of response rates? - Management noted that both agencies are supportive and expect compelling data, with a response rate above 25% being favorable [43] Question: How should we think about TakeAim Leukemia? - Management emphasized caution regarding data expectations in leukemia but highlighted ongoing studies and interest in monotherapy extensions [50][55]

Financial Data and Key Metrics Changes - The company's net revenue for 2024 increased approximately 20% to about $11.7 million compared to $9.8 million in 2023 [6][40] - Total net revenue for Q4 2024 was approximately $3.5 million, representing a 53% increase from Q4 2023's $2.3 million and a 13% increase from Q3 2024's $3.1 million [6][40] - Loss from operations decreased from $34.3 million in 2023 to $30.8 million in 2024 [41] - Net loss attributable to common shareholders decreased from $41.3 million in 2023 to $38.5 million in 2024 [42] Business Line Data and Key Metrics Changes - Mytesi prescription volume increased approximately 3.9% in 2024 compared to 2023 [41] - Mytesi prescription volume increased by about 9.4% in Q4 2024 over Q4 2023 [41] Market Data and Key Metrics Changes - The company is focusing on rare diseases and supportive care for cancer patients, particularly targeting intestinal failure and cancer therapy-related diarrhea [10][32] Company Strategy and Development Direction - The company is pursuing multiple near-term catalysts expected in Q2 2025, which are viewed as significant and value-enhancing [7][43] - The focus is on developing crofelemer for rare diseases and expanding Mytesi's indications to include cancer therapy-related diarrhea [26][36] Management's Comments on Operating Environment and Future Outlook - Management emphasized the importance of upcoming catalysts and the potential for significant collaborations and licensing deals [13][43] - The company is optimistic about the potential for crofelemer to receive fast-track designations from regulatory agencies due to the lack of approved treatments for certain conditions [25][27] Other Important Information - The company is conducting ongoing proof-of-concept trials for crofelemer in rare diseases, with initial results expected in Q2 2025 [21][22] - The company has developed a novel formulation of crofelemer specifically for patients with intestinal failure, which differs from the commercialized version [30][29] Q&A Session Summary - No specific questions or answers were provided in the content regarding the Q&A session [46]